Clinical trial
Glioma Developmental and HyperActive Ras Tumor (DHART) Board
NCT05489783 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Glioma Developmental and HyperActive Ras Tumor (DHART) Board
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- July 29, 2022
- Completion date
- July 31, 2027
- Enrollment
- 50 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.